Valion Bio, Inc. (VBIO), formerly known as Tivic Health Systems, Inc., completed a significant corporate transformation in April 2026. Headquartered in San Antonio, Texas, the company operates as a late-stage biopharmaceutical entity specializing in the advancement of biologics that activate innate immune pathways. The company's primary asset, Entolimod, is a TLR5 agonist currently in late-stage development for the treatment of acute radiation syndrome. Beyond its radioprotection focus, Valion Bio is actively researching the application of Entolimod for the treatment of Neutropenia and lymphocyte exhaustion. Furthermore, the company is developing Entolasta, an immunologically optimized variant of Entolimod designed for chronic applications, such as addressing immunosenescence. The company leverages its facility in San Antonio to maintain close ties with the local DoD biodefense ecosystem. Beyond drug development, Valion Bio offers Contract Development and Manufacturing Organization (CDMO) services, positioning itself as both a product developer and a service provider in the healthcare sector. Financially, the company operates with a lean structure, reporting 52 employees and a market capitalization of approximately $915,436 as of the most recent reporting. The firm is currently in a capital-intensive phase, with significant historical investment totaling over $140 million. Management, led by CEO Michael K. Handley, is focused on the successful clinical progression of its pipeline assets. Key risks for the company include its current negative profit margins and the inherent uncertainty of late-stage clinical trials. Despite these challenges, the strategic pivot from medical device manufacturing to biopharmaceutical development underscores a commitment to high-value therapeutic markets. Valion Bio's business model relies on the eventual commercialization of its proprietary agonist platforms, aiming to provide solutions for both acute medical emergencies and chronic age-related immune decline. Investors should note the company's limited historical data under the new corporate identity and its current stage in the drug development life cycle.
U.S. National Institute of Allergy and Infectious Diseases (NIAID)U.S. Department of Defense / Defense Threat Reduction Agency (DTRA) / Armed Forces Radiobiology Research Institute (AFRRI)Biomedical Advanced Research and Development Authority (BARDA)Sheba Medical Center (Tel HaShomer, Israel)U.S. House Armed Services Committee
